Emergent Biosolutions Stock Target Price and Analyst Consensus

EBS
 Stock
  

USD 31.09  0.05  0.16%   

The current analyst and expert consensus on Emergent Biosolutions is Hold with 4 hold recommendations. The current projected Emergent Biosolutions target price consensus is 62.5 with 4 analyst opinions. One of the most common ways Emergent Biosolutions analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Emergent Biosolutions vendors, executives, and/or customers. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Emergent Biosolutions. We strongly encourage you to use your own analysis of Emergent Biosolutions to validate this buy or sell advice. Emergent Biosolutions recommendation module provides expert sentiment on the projected Emergent Biosolutions target price to derive its highest and lowest estimates based on target price standard deviation of 10.847. Continue to Macroaxis Advice on Emergent Biosolutions to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
Refresh
As of 07/01/2022, Gross Profit is likely to drop to about 825.7 M. In addition to that, Profit Margin is likely to drop to 11.54. Emergent Biosolutions Shareholders Equity is relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Shareholders Equity of 1.62 Billion. As of 07/01/2022, Inventory is likely to grow to about 378.5 M, while Assets Non Current are likely to drop slightly above 1.4 B.

Emergent Biosolutions Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Emergent target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Emergent target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions6
Lowered Outlook0
Raized Outlook0
Hold
Most Emergent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Emergent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Emergent Biosolutions, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Emergent Biosolutions Target Price Projection

Emergent Biosolutions' current and average target prices are 31.09 and 62.50, respectively. The current price of Emergent Biosolutions is the price at which Emergent Biosolutions is currently trading. On the other hand, Emergent Biosolutions' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Emergent Biosolutions Market Quote on 1st of July 2022

Low Price30.43Odds
High Price31.57Odds

31.09

Target Price

Analyst Consensus On Emergent Biosolutions Target Price

Low Estimate50.0Odds
High Estimate75.0Odds
Number of Analysts4
Standard Deviation10.847

62.5

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Emergent Biosolutions and the information provided on this page.

Emergent Biosolutions Analyst Ratings

Emergent Biosolutions' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Emergent Biosolutions stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Emergent Biosolutions' financials, market performance, and future outlook by experienced professionals. Emergent Biosolutions' historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Emergent Biosolutions Target Price Projections

Emergent Biosolutions's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Emergent Biosolutions and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Emergent depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Emergent Biosolutions including analysis of its current option contracts.
Emergent Biosolutions' latest option contracts expiring on 2022-07-15 are carrying combined implied volatility of 94.81 with a put-to-call open interest ratio of 0.19 over 20 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2022-07-15. The current put volume is at 14, with calls trading at the volume of 632. This yields a 0.02 put-to-call volume ratio. The Emergent Biosolutions option chain provides detailed quote and price information for the current Emergent Biosolutions option contracts. It shows all of Emergent Biosolutions' listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2022-07-15 Option Contracts

Emergent Biosolutions option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Emergent Biosolutions' lending market. For example, when Emergent Biosolutions' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Emergent Biosolutions, he or she must hedge the risk by shorting Emergent Biosolutions stock over its option's life.
The chart above shows Emergent Biosolutions' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Emergent Biosolutions' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Emergent Biosolutions' option, there is no secondary market available for investors to trade.

Emergent Biosolutions Maximum Pain Price across 2022-07-15 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Emergent Biosolutions close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Emergent Biosolutions' stock options are financial instruments that give investors the right to buy or sell shares of Emergent Biosolutions common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Emergent stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Emergent Biosolutions' stock price goes up or down, the stock options follow.
Continue to Macroaxis Advice on Emergent Biosolutions to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Emergent Biosolutions In The Money Call Balance

When Emergent Biosolutions' strike price is surpassing the current stock price, the option contract against Emergent Biosolutions stock is said to be in the money. When it comes to buying Emergent Biosolutions' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' options written on Emergent Biosolutions are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Emergent Current Options Market Mood

Emergent Biosolutions' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Emergent Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Emergent Biosolutions' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Emergent Biosolutions' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Emergent Biosolutions' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional Emergent Biosolutions Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Emergent Biosolutions is a key component of Emergent Biosolutions valuation and have some predictive power on the future returns of a Emergent Biosolutions.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Emergent Biosolutions' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Emergent Biosolutions in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
25.7030.0734.44
Details
Intrinsic
Valuation
LowReal ValueHigh
27.9438.5642.93
Details
Naive
Forecast
LowNext ValueHigh
30.6735.0439.42
Details
Earnings
Estimates (4)
LowProjected EPSHigh
4.695.416.28
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Emergent Biosolutions. Your research has to be compared to or analyzed against Emergent Biosolutions' peers to derive any actionable benefits. When done correctly, Emergent Biosolutions' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Emergent Biosolutions.

Additional Emergent Biosolutions Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Emergent Biosolutions is a key component of Emergent Biosolutions valuation and have some predictive power on the future returns of a Emergent Biosolutions.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Emergent Biosolutions' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Emergent Biosolutions in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
25.7030.0734.44
Details
Intrinsic
Valuation
LowReal ValueHigh
27.9438.5642.93
Details
Naive
Forecast
LowNext ValueHigh
30.6735.0439.42
Details
Earnings
Estimates (4)
LowProjected EPSHigh
4.695.416.28
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Emergent Biosolutions. Your research has to be compared to or analyzed against Emergent Biosolutions' peers to derive any actionable benefits. When done correctly, Emergent Biosolutions' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Emergent Biosolutions.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested less than 1 share
Continue to Macroaxis Advice on Emergent Biosolutions to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
The data published in Emergent Biosolutions' official financial statements usually reflect Emergent Biosolutions' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Emergent Biosolutions. For example, before you start analyzing numbers published by Emergent accountants, it's critical to develop an understanding of what Emergent Biosolutions' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Emergent Biosolutions' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Emergent Biosolutions' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Please utilize our Beneish M Score to check the likelihood of Emergent Biosolutions' management to manipulate its earnings.